@fordham1

Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos

, , , , , , , , , and . QJM: An International Journal of Medicine, (January 2021)
DOI: 10.1093/qjmed/hcab035

Description

Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos | medRxiv

Links and resources

Tags